Retatrutide Dosing in Trials, Units Chart & Half-Life
[GLP-1 · Compound guide]

Retatrutide: reconstitution, units and half-life

Vial sizes · Worked example · Units chart · Half-life ~6 days

Short answer: Retatrutide has a half-life of about 6 days (144 hours). After about 5 half-lives, roughly 97% of a dose is gone, so it is mostly cleared about 30 days (720 hours) after the last dose. People vary, so treat these as estimates.

What is retatrutide?

Retatrutide (LY3437943) is an investigational drug from Eli Lilly that acts on GIP, GLP-1 and glucagon receptors. It is not FDA approved as of October 2026.

Also known as: LY3437943.

Common vial sizes

There is no approved retatrutide product. Powder vials are most often labeled 10 mg, 20 mg or 30 mg; 5 mg, 15 mg, 40 mg, 50 mg and 60 mg vials are also common.

Water and syringe-unit charts by vial size: 5 mg · 10 mg · 15 mg · 20 mg · 30 mg · 40 mg · 50 mg · 60 mg

Worked reconstitution example

Here is the math for a 10 mg vial mixed with 2 mL of bacteriostatic water, drawing 2 mg with a U-100 insulin syringe (1 mL = 100 units).

  1. Concentration. 10 mg ÷ 2 mL = 5 mg/mL
  2. Volume to draw. 2 mg ÷ 5 mg/mL = 0.4 mL
  3. Syringe units. 0.4 mL × 100 = 40 units
The amount here is an example to show the math, not a recommendation. How much to take is a decision for you and your prescriber.

Units chart at 5 mg/mL

10 mg vial + 2 mL water. Amounts are examples for the conversion, not doses.
AmountVolumeU-100 syringe
1 mg0.2 mL20 units
2 mg0.4 mL40 units
4 mg0.8 mL80 units

Same amount, different water volumes

Adding more water doesn't change how much retatrutide is in the vial. It only spreads it over more liquid, so each draw is bigger and easier to read.

2 mg from a 10 mg vial.
Water addedConcentrationVolumeU-100 syringe
1 mL10 mg/mL0.2 mL20 units
2 mL5 mg/mL0.4 mL40 units
3 mL3.33 mg/mL0.6 mL60 units
5 mL2 mg/mL1 mL100 units

For any other vial size or amount, the free peptide reconstitution calculator works backwards from the amount you want and suggests a water volume that lands on a clean syringe mark.

What doses of retatrutide were studied?

Retatrutide is given once a week. In the phase 2 obesity trial (Jastreboff, NEJM 2023; 338 adults, 48 weeks), people were randomized to placebo or 1, 4, 8 or 12 mg. The higher doses were reached by stepping up every 4 weeks: 4 mg started at 2 or 4 mg, 8 mg went 2 → 4 → 8 or 4 → 8, and 12 mg went 2 → 4 → 8 → 12.

Phase 2 obesity trial (Jastreboff 2023): mean body-weight change.
GroupWeek 24Week 48
Placebo−1.6%−2.1%
1 mg−7.2%−8.7%
4 mg−12.9%−17.1%
8 mg−17.3%−22.8%
12 mg−17.5%−24.2%

In the phase 2 type 2 diabetes trial (Rosenstock, Lancet 2023; 281 adults, 36 weeks), arms ran from 0.5 mg to 12 mg, including 4 mg and 8 mg arms with different escalation speeds, against placebo and dulaglutide 1.5 mg. At 24 weeks HbA1c fell by 2.02 percentage points on 12 mg versus 1.41 on dulaglutide; body weight fell 16.94% on 12 mg at 36 weeks.

The phase 3 TRIUMPH trials test 4, 9 and 12 mg once weekly. Everyone starts at 2 mg and steps up every 4 weeks through 2, 4, 6, 9 and 12 mg until reaching their assigned dose, then stays there.

These are trial protocols, not personalized advice; confirm any dosing with your prescriber.

Where is retatrutide in approval?

As of October 17, 2026, retatrutide is not approved in any country. Eli Lilly has said it plans to submit it to the FDA in the first quarter of 2027. Phase 3 results so far (mean weight change on the efficacy estimand, versus placebo):

  • TRIUMPH-4 (announced December 11, 2025; 445 adults with obesity and knee osteoarthritis, 68 weeks): −26.4% on 9 mg and −28.7% on 12 mg, versus −2.1%.
  • TRANSCEND-T2D-1 (March 19, 2026; 537 adults with type 2 diabetes, 40 weeks): HbA1c −1.7, −2.0 and −1.9 points on 4, 9 and 12 mg versus −0.8; weight −11.5%, −15.5% and −16.8% versus −2.5%.
  • TRIUMPH-1 (May 21, 2026; 2,339 adults, 80 weeks; published in NEJM September 29, 2026): −19.0%, −25.9% and −28.3% on 4, 9 and 12 mg, versus −2.2%.
  • TRIUMPH-2 (July 23, 2026; 1,152 adults with obesity and type 2 diabetes): −12.7%, −19.1% and −20.8% on 4, 9 and 12 mg, versus −4.0%.
  • TRIUMPH-3 (July 23, 2026; 1,949 adults with a BMI of 35 or more and cardiovascular disease): −21.6% on 9 mg and −22.6% on 12 mg, versus −3.2%.

Until there is an approved product, there is no FDA label with dosing, storage or safety instructions. For how retatrutide compares with tirzepatide, see retatrutide vs tirzepatide.

How many units is X mg of retatrutide?

It depends only on the concentration in your vial. The table shows syringe units on a U-100 insulin syringe (1 mL = 100 units) at four common vial and water combinations. The amounts are the doses used in the trials above, shown for the conversion only.

Retatrutide amount to U-100 syringe units. Amounts are trial doses, not recommendations.
Amount5 mg + 2 mL (2.5 mg/mL)10 mg + 2 mL (5 mg/mL)20 mg + 2 mL (10 mg/mL)30 mg + 2 mL (15 mg/mL)
1 mg40 units20 units10 units6.7 units
2 mg80 units40 units20 units13.3 units
4 mgover 1 mL80 units40 units26.7 units
6 mgover 1 mLover 1 mL60 units40 units
8 mgover 1 mLover 1 mL80 units53.3 units
9 mgover 1 mLover 1 mL90 units60 units
12 mgover 1 mLover 1 mLover 1 mL80 units

Formula: amount ÷ (vial mg ÷ water mL) × 100 = units. For any other vial or water volume, use the reconstitution calculator, or see the GLP-1 units guide.

Retatrutide half-life and time to peak

  • Half-lifeabout 6 days (144 hours)
  • Time to peak (Tmax)Not listed
  • Route in Dose TrackUnder the skin (subcutaneous)

A phase 1b trial (Urva 2022) reported a half-life of about 6 days. We could not confirm a published time to peak, so we leave it out.

Numbers shown are the values Dose Track uses, listed only where they agree with the source above. Half-life varies from person to person and with injection site.

How to track retatrutide in Dose Track

  1. Add retatrutide from the built-in list. It sits next to everything else you take, so a GLP-1, TRT and a few peptides all live in one log.
  2. Save your vial: enter the vial size and how much water you added. From then on every amount you log shows as syringe units, and the reconstitution planner suggests a water volume that lands on a clean mark.
  3. Log each shot. The app subtracts it from the vial, shows what is left, and warns you before you run out.
  4. Set reminders on your own schedule, whether that is daily, weekly or every few days.
  5. Your log is stored on your phone and no account is needed. Data only leaves it for features you choose, like AI answers and lab reading.

Retatrutide tracker · How Dose Track handles GLP-1s · Reconstitution calculator · Half-life calculator

Frequently asked questions

How much bacteriostatic water do I add to a 10 mg retatrutide vial?+
There is no single right amount. More water makes each draw bigger and easier to measure; less water makes it smaller. For example, 2 mL in a 10 mg vial gives 5 mg/mL, so 2 mg is 0.4 mL, or 40 units on a U-100 insulin syringe. That amount is only an example for the math, not a recommendation. The free Dose Track reconstitution calculator works it out for any vial and amount.
How many units is 2 mg of retatrutide?+
It depends on the concentration in your vial. At 5 mg/mL (10 mg mixed with 2 mL), 2 mg is 0.4 mL, which is 40 units on a U-100 insulin syringe, where 1 mL is 100 units. Divide the amount by the concentration to get mL, then multiply by 100.
What is the half-life of retatrutide?+
Dose Track uses a half-life of about 6 days (144 hours) for retatrutide. A phase 1b trial (Urva 2022) reported a half-life of about 6 days. We could not confirm a published time to peak, so we leave it out.
What doses of retatrutide were studied in trials?+
In the phase 2 obesity trial (Jastreboff, NEJM 2023), adults took 1, 4, 8 or 12 mg once weekly or placebo for 48 weeks; the 4, 8 and 12 mg groups mostly started at 2 mg and stepped up every 4 weeks (for example 2, 4, 8, then 12 mg). The phase 3 TRIUMPH trials test 4, 9 and 12 mg once weekly, starting at 2 mg and stepping up every 4 weeks through 2, 4, 6, 9 and 12 mg. These are trial protocols, not personalized advice; confirm any dosing with your prescriber.
Is retatrutide FDA approved?+
No. As of October 17, 2026, retatrutide is not approved in any country. Eli Lilly has reported phase 3 results from TRIUMPH-4 (December 2025), TRANSCEND-T2D-1 (March 2026), TRIUMPH-1 (May 2026) and TRIUMPH-2 and TRIUMPH-3 (July 2026), and has said it plans to submit to the FDA in the first quarter of 2027.
Can I track retatrutide in Dose Track?+
Yes. Retatrutide is built into Dose Track. You can log each shot next to your other compounds, save your vial and how much water you added so every amount shows in syringe units, see how much is left in the vial, and get reminders. Your log is stored on your phone and no account is needed. Data only leaves it for features you choose, like AI answers and lab reading.